Kymera Therapeutics
Michael Fitzgerald is a seasoned scientist with extensive experience in cancer pharmacology and immunobiology. Currently serving as a Senior Scientist at Kymera Therapeutics since November 2020, Fitzgerald previously held roles at Takeda Oncology as a Consultant and as a Scientist I, where significant contributions included leading discovery projects focused on protein homeostasis and overseeing pharmacology efforts for the development of various cancer therapeutics. Fitzgerald's earlier experience includes research investigations at Millennium Pharmaceuticals and Wyeth Biotech, concentrating on autoimmune disease models and hematopoietic stem cell biology, respectively. With a degree from Virginia Commonwealth University, Fitzgerald has consistently demonstrated expertise in designing and executing complex pharmacological studies and managing collaborative research initiatives.
Kymera Therapeutics
5 followers
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.